Literature DB >> 30950979

Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis.

Guido Grassi1, Graziella D'Arrigo2, Anna Pisano2, Davide Bolignano2, Francesca Mallamaci2, Raffaella Dell'Oro1, Fosca Quarti-Trevano1, Gino Seravalle3, Giuseppe Mancia3,4, Carmine Zoccali2.   

Abstract

BACKGROUND AND OBJECTIVES: Sympathetic neural activation occurs in congestive heart failure (CHF). However, the small sample size of the microneurographic studies, heterogeneity of the patients examined, presence of comorbidities as well as confounders (including treatment) represented major weaknesses not allowing to identify the major features of the phoenomenon, particularly in mild CHF. This meta-analysis evaluated 2530 heart failure (CHF) patients recruited in 106 microneurographic studies. It was based on muscle sympathetic nerve activity (MSNA) quantification in CHF of different clinical severity, but data from less widely addressed conditions, such as ischemic vs. idiopathic, were also considered.
METHODS: Assessment was extended to the relationships of MSNA with venous plasma norepinephrine, heart rate (HR) and echocardiographic parameters of cardiac morphology [left ventricular (LV) end-diastolic diameter] and function (LV ejection fraction) as well.
RESULTS: MSNA was significantly greater (1.9 times, P < 0.001) in CHF patients as compared with healthy controls, a progressive significant increase being observed from New York Heart Association classes I-IV in unadjusted and adjusted analyses. MSNA was significantly greater in both untreated and treated CHF (P < 0.001 for both), related to left ventricular (LV) end-diastolic diameter and to a lesser extent to LV ejection fraction (r = 0.24 and -0.05, P < 0.001 and <0.01, respectively), and closely associated with HR (r = 0.66, P < 0.001) and plasma norepinephrine (r = 0.68, P < 0.001).
CONCLUSION: CHF is characterized by sympathetic overactivity which mirrors the degree of LV dysfunction independently of the stage of CHF, its cause and presence of confounders or pharmacological treatment. plasma norepinephrine and HR represent potentially valuable surrogate markers of sympathetic activation in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30950979     DOI: 10.1097/HJH.0000000000002093

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  11 in total

Review 1.  Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options.

Authors:  Edoardo Gronda; Emilio Vanoli; Stefania Sacchi; Guido Grassi; Giuseppe Ambrosio; Claudio Napoli
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 2.  Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings.

Authors:  Guido Grassi; Fosca Quarti Trevano; Raffaella Dell'Oro; Gino Seravalle; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2019-10-10       Impact factor: 5.369

Review 3.  Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.

Authors:  Kunihiro Matsushita; Shoshana H Ballew; Angela Yee-Moon Wang; Robert Kalyesubula; Elke Schaeffner; Rajiv Agarwal
Journal:  Nat Rev Nephrol       Date:  2022-09-14       Impact factor: 42.439

Review 4.  Sympathetic and Vagal Nerve Activity in COPD: Pathophysiology, Presumed Determinants and Underappreciated Therapeutic Potential.

Authors:  Jens Spiesshoefer; Binaya Regmi; Matteo Maria Ottaviani; Florian Kahles; Alberto Giannoni; Chiara Borrelli; Claudio Passino; Vaughan Macefield; Michael Dreher
Journal:  Front Physiol       Date:  2022-06-23       Impact factor: 4.755

Review 5.  Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair.

Authors:  Jordana I Borges; Krysten E Ferraino; Natalie Cora; Deepika Nagliya; Malka S Suster; Alexandra M Carbone; Anastasios Lymperopoulos
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

Review 6.  Studying Cardiac Neural Network Dynamics: Challenges and Opportunities for Scientific Computing.

Authors:  Nil Z Gurel; Koustubh B Sudarshan; Sharon Tam; Diana Ly; J Andrew Armour; Guy Kember; Olujimi A Ajijola
Journal:  Front Physiol       Date:  2022-04-29       Impact factor: 4.755

Review 7.  Sympathetic activation in congestive heart failure: an updated overview.

Authors:  Guido Grassi; Fosca Quarti-Trevano; Murray D Esler
Journal:  Heart Fail Rev       Date:  2021-01       Impact factor: 4.214

8.  Sympathetic activation in heart failure with reduced and mildly reduced ejection fraction: the role of aetiology.

Authors:  Réka Urbancsek; Zoltán Csanádi; Ildikó Noémi Forgács; Tímea Bianka Papp; Judit Boczán; Judit Barta; Csaba Jenei; László Nagy; László Rudas
Journal:  ESC Heart Fail       Date:  2021-09-07

9.  Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Josef Stehlik; Adam S Smith; Russell S Richardson; D Walter Wray
Journal:  Auton Neurosci       Date:  2021-06-24       Impact factor: 2.355

10.  The Sympathetic Nervous System in Hypertension: Roadmap Update of a Long Journey.

Authors:  Guido Grassi
Journal:  Am J Hypertens       Date:  2021-12-01       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.